It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The strength of the T cell receptor interaction with self-ligands affects antigen-specific immune responses. However, the precise function and underlying mechanisms are unclear. Here, we demonstrate that naive CD8+ T cells with relatively high self-reactivity are phenotypically heterogeneous owing to varied responses to type I interferon, resulting in three distinct subsets, CD5loLy6C–, CD5hiLy6C–, and CD5hiLy6C+ cells. CD5hiLy6C+ cells differ from CD5loLy6C– and CD5hiLy6C– cells in terms of gene expression profiles and functional properties. Moreover, CD5hiLy6C+ cells demonstrate more extensive antigen-specific expansion upon viral infection, with enhanced differentiation into terminal effector cells and reduced memory cell generation. Such features of CD5hiLy6C+ cells are imprinted in a steady-state and type I interferon dependence is observed even for monoclonal CD8+ T cell populations. These findings demonstrate that self-reactivity controls the functional diversity of naive CD8+ T cells by co-opting tonic type I interferon signaling.
There is heterogeneity in the response to self-ligands within the naïve CD8+ T cell pool and the consequences of this are unclear. Here the authors show subsets of naïve CD8+ T cells which differ in expression of Ly6C and CD5 and response to viral infection through regulation by type I IFN signalling.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Seoul National University, Department of Agricultural Biotechnology and Research Institute of Agriculture and Life Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
2 Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology, Pohang, Korea (GRID:grid.49100.3c) (ISNI:0000 0001 0742 4007); Chonnam National University Medical School, Department of Microbiology and Immunology and Medical Research Center for Combinatorial Tumor Immunotherapy, Hwasun, Korea (GRID:grid.14005.30) (ISNI:0000 0001 0356 9399); Immunotherapy Innovation Center, Chonnam National University Medical School, Hwasun Hospital, Hwasun, Korea (GRID:grid.14005.30) (ISNI:0000 0001 0356 9399)
3 Immunotherapy Innovation Center, Chonnam National University Medical School, Hwasun Hospital, Hwasun, Korea (GRID:grid.14005.30) (ISNI:0000 0001 0356 9399)
4 Chonnam National University Medical School, Department of Microbiology and Immunology and Medical Research Center for Combinatorial Tumor Immunotherapy, Hwasun, Korea (GRID:grid.14005.30) (ISNI:0000 0001 0356 9399); Immunotherapy Innovation Center, Chonnam National University Medical School, Hwasun Hospital, Hwasun, Korea (GRID:grid.14005.30) (ISNI:0000 0001 0356 9399); BioMedical Sciences Graduate Program, Chonnam National University Medical School, Hwasun, Korea (GRID:grid.14005.30) (ISNI:0000 0001 0356 9399)